www.fgks.org   »   [go: up one dir, main page]
WebMD: Better Information. Better Health.
Skip to content
Other search tools:Symptoms|Doctors|Hospitals

Alzheimer's Disease Center for Caring

Sponsored byForest Namenda PAC image
The following is a Sponsored Resource. The sponsor of this content has sole editorial control.
10 Questions to Ask Your Doctor about Alzheimer's Disease and Namenda

Speaking about the person with Alzheimer's disease, ask:

1. How would you categorize his/her current symptoms today: mild, moderate, or severe? What does that mean?

2. How will his/her symptoms change over time?

3. Could treating him/her with Alzheimer's disease medication [or, changing to a different Alzheimer's disease medication] help slow the decline in symptoms?

4. What are the key differences among the Alzheimer's disease treatments available today?

5. What are the potential benefits and risks of treatment and non-treatment?

6. Which of these medications are you considering for him/her now?

7. I've heard Namenda works differently from other Alzheimer's disease medications and can be used in combination with another Alzheimer's medication. Would you consider prescribing Namenda for him/her?

8. I completed this assessment on WebMD. Does this information help you in considering if Namenda is right for him/her?

9. How will I know when I should contact you again about his/her Alzheimer's disease medication?

10. Is there anything else that I should be doing for him/her or for myself?

Information for the Doctor About Namenda® (memantine HCl)

Namenda (memantine HCl), approved on October 16, 2003, by the U.S. Food and Drug Administration, is indicated for the treatment of moderate to severe Alzheimer's disease. Namenda is the only product in a class of medications, called NMDA (N-methyl-D-aspartate)- receptor antagonists, which treat Alzheimer's disease with a mechanism of action distinct from other currently available drugs. Namenda is administered orally at a recommended dose of 10 mg twice daily following a four-week titration.

In clinical trials, Namenda has excellent safety and tolerability. Namenda is contraindicated in patients with known hypersensitivity to memantine HCl or to any excipients used in the formulation. The most common adverse events reported with Namenda vs placebo (greater or than or equal to 5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced.

For more information about Namenda for your patients with moderate or severe symptoms of Alzheimer's disease, please visit www.namenda.com or contact your Forest Laboratories representative.

Next Article:

Safety information

Namenda (memantine HCl) is contraindicated in patients with known hypersensitivity to memantine HCl or to any excipients used in the formulation. The most common adverse events reported with Namenda vs. placebo (≥5% and higher than placebo) were dizziness, confusion, headache, and constipation. In patients with severe renal impairment, the dosage should be reduced.

Namenda is indicated for the treatment of moderate to severe Alzheimer's disease.

Full Prescribing Information | Global Reference List

© 2007 Forest Pharmaceuticals, Inc

WebMD does not endorse any specific product, service, or treatment.

Namenda Works Differently to Treat Alzheimer's Disease

Namenda is safe and effective

Starting Namenda is easy

When to ask about Namenda therapy

FREE Email Newsletter

"Healthier Living with Alzheimer's Disease"

Listen in to the Experts

As a caregiver, what should you expect from talking with your doctor? Dr. Lesley Blake shares information on how to prepare for these critical dialogues, from how the doctor will want to "examine" both caregiver and patient and what treatments may be offered.

Series moderated by: Warachal E. Faison, MD, Assistant Director of the Institute of Research Minority Training on Mental Health and Aging (IRMMA) and Clinical Director of the Alzheimer's Research and Clinical Programs at the Medical University of South Carolina.

More Expert Audio